Relmada Therapeutics (RLMD) Amortization of Deferred Charges (2014 - 2017)
Relmada Therapeutics (RLMD) reported Amortization of Deferred Charges of $2819.0 for Q3 2017, down 96.42% on a QoQ basis from $78724.0 in Q2 2014.
Relmada Therapeutics (RLMD) has 2 years of Amortization of Deferred Charges data on file, last reported at $2819.0 in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 2,819.00 |
| Sep 30, 2017 | 2,819.00 |
| Jun 30, 2014 | 78,724.00 |
| Jun 30, 2014 | 78,724.00 |
| Mar 31, 2014 | 65,760.00 |
| Mar 31, 2014 | 65,760.00 |